Lymenet.de - Home Neues auf Lymenet.de Ergänzungen und Veränderungen Über Lyme-Borreliose Klinische Informationen  Symptome, Diagnose, Behandlung  Hintergrund & medizinische Fachliteratur Lyme und Multiple Sklerose Lyme und ALS Berichte über Tagungen und Info-Veranstaltungen Krankenversicherungen Menschenrechte, Ethik Beiträge von Selbsthilfegruppen Artikel in Zeitschriften und TV Lexikon Kontakte Links Suchen FAQs: Häufig gestellte Fragen Hinweise zum Offline-Lesen Dateistruktur von Lymenet.de

Medical Literature Medizinische Fachliteratur International Conference on Lyme Disease and Other Spirochetal and Tick-Borne Disorders (cached versions) 12th International Conference, April 9 - 10, 1999, April 9 April 10 14th International Conference, 2001 Abstracts von Veröffentlichungen in medizinischen Fachzeitschriften Allicin: A Medline Literature Survey (Date: 26. April 2000) Amantadin Stada 100mg (Cache date: June 30, 2005) Manfred von Ardenne: Research on Hyperbaric Oxygen Pressure Therapy and Cancer Therapy, A Medline-Literature Survey (Date: 13. June 1999) Asymptomatic Lyme, from: jwissmille@aol.com (JWissmille), Newsgroups: sci.med.diseases.lyme, Subject: old post--asymptomatic Lyme disease (28 Jan 1999) Atovaquone (Meprone) - For educational use only Bakken LL, Callister SM, Wand PJ, Schell RF, Interlaboratory comparison of test results for detection of Lyme disease by 516 participants in the Wisconsin State Laboratory of Hygiene/College of American Pathologists Proficiency Testing Program, J Clin Microbiol 1997 Mar;35(3):537-43 Barbour, AG, Advanced Query, Search Field: Author, Suchbegriff: Barbour AG (31. July 1998) Barkley MS, Transscript of a testimony,  New York State Assembly Standing Committee on Health, Public, Hearing "Chronic Lyme Disease and Long-Term Antibiotic Treatment", Albany, NY, USA, (27.11.2001, pp. 199 - 227). Carol Ann Campbell, Hoffnung für Lyme-Borreliose-Patienten, Star-Ledger, Medicine (4. Okt.2001) Isolates of Borrelia spp. Brand R and Kelman J, Physicians' Perspective on Chronic Lyme, Rockland Journal-News (20. October, 2003) Brorson O, Brorson SH, Henriksen TH, Skogen PR, Schoyen R., Association between multiple sclerosis and cystic structures in cerebrospinal fluid, Infection 2001 Dec;29(6):315-9 Burrascano JJ, 1994 California Lyme Disease Symposium - Lyme Disease Resource Center of California Clearance, Halbwertszeit Lyme Disease: Studies on the Cystic Form of Borrelia burgdorferi and Mechanisms of Persistence. Original at Lymeinfo.net (September 2003) Cystic Form of Bb: An Introduction (in cache, January 2011): "These abstracts shed light on how Borrelia burgdorferi (Bb) is able to survive antibiotic therapy, and on a primary mechanism underlying post-treatment clinical relapses. They document the ability of Bb to change from a spirochete-form to a "cystic" or coccoid form in response to adverse environmental conditions. The cystic forms can later regenerate spirochetes. 17 pages. Last modified: September 2003 " Cystic Form of Bb & Other Spirochetes: Advanced: "*Highly Recommended*. This file juxtaposes photographs and quotations from studies dating as far back as the early 1900's to show how spirochetes can transform to and from cystic or coccoid forms. The ability of Bb and other spirochetes to exist in coccoid forms provides a cogent explanation for phenomenon such as latency, persistent infection, and seronegativity. A picture is worth a thousand words! 30 pages. Last modified: September 2003" Cystic Forms of Spirochetes: A Complete Bibliography, 1905-Present: "Especially helpful for researchers. This file contains a complete bibliography of over 260 studies with information/observations on round forms of spirochetes (including 63 studies pertaining to Lyme disease), dating from the early 1900's to the present. Relevant quotations from the studies are included. 53 pages. Last modified: November 2010" Cysts: Environmental Adaptation of Spirochetes (09 Apr 2000) Cysts: Historical Observations of Spirochetal Cysts and L-Forms (09 Apr 2000) Differentialblutbild, H. Begemann: Praktische Hämatologie, 8. Aufl.; Stuttgart (1982) Drulle J, Lyme Disease: The Pitfalls of Laboratory Testing (in: Lora Mermin (editor), Lyme Disease 1991: Patient/Physician Perspective from the U.S. and Canada) Lyme Disease 1991; Patient/Arzt-Perspektiven aus den Vereinigten Staaten und Kanada, L. Mermin (Ed.) Antibiotika und Steroide, Antibiotics and Steroids Uta Everth, U. Weller, A. Waldherr, VIIIth International Potsdam Symposium on Tick-borne Diseases, Jena, Germany, March 3 - 13, 2005 (im Cache) Borreliose-Serologie (im Cache) Selected Aspects of Serology of Borrelia burgdorferi sensu lato (im Cache) Zielwertfindung und Standards in der Borrelien-Serologie" in "Lyme-Borreliose, Koinfektionen und Multisystemerkrankungen", Deutsche Borreliose-Gesellschaft, Bad Herrenalb, 28. - 30. 5. 2010. Felice A, Brian A. Fallon, Psychiatric and neuropsychological aspects of Lyme Disease, Meeting of the American Psychiatric Association (2002) Flagyl (Metronidazole) & CSF, A Medline Literature Survey "metronidazole AND csf", Date: April 19, 2000 Gasser R, Orale Behandlung der späten Lyme-Borreliose mit Roxithromycin und Co-trimoxazol, THE LANCET, VOL. 337, JAN 26, 1991, page 241 Generation Time, The generation time of a single cell is the duration TG of a cell cycle, measured as the time between two consecutive mitoses. Golde WT et al., Immune Response and Western Blotting, Literature selected by Kathleen M. Dickson and presented Oct. 9, 1999 for comment at the Lyme-L Discussion List Hanegraaf W, Simulating the Immune System (August 10, 2001) Lyme and Head, Neck and Hearing Disorders Hydroxychloroquin - Chloroquin (Engl. version): Pharmacokinetische Daten, Erklärung der Begriffe "Clearance", "Verteilungsvolumen" und Eliminationshalbwertszeit Goodman & Gilman's "Pharmacological Basis of Therapeutics": Toxizität und Nebenwirkungen Hydroxychloroquin und Lyme Weiterführende Literatur The ILADS Working Group, Evidence-based guidelines for the management of Lyme disease, Expert Rev Antiinfect Ther 2004;2(1 Suppl):S1-13 (im Cache). This report, completed in November 2003, is intended to serve as a resource for physicians, public health officials and organizations involved in the evaluation and treatment of Lyme disease. (Report Summary) Highlights of Guidelines Since there is currently no definitive test for Lyme disease, laboratory results should not be used to exclude an individual from treatment. Lyme disease is a clinical diagnosis and tests should be used to support rather than supersede the physician's judgment. The early use of antibiotics can prevent persistent, recurrent, and refractory Lyme disease. The duration of therapy should be guided by clinical response, rather than by an arbitrary (i.e., 30 day) treatment course. The practice of stopping antibiotics to allow for delayed recovery is not recommended for persistent Lyme disease. In these cases, it is reasonable to continue treatment for several months after clinical and laboratory abnormalities have begun to resolve and symptoms have disappeared. in Cache: Diagnostic Concerns in Cache: Treatment Considerations, e.g. combination antibiotic treatment with oral amoxicillin, cefuroxime, or (more recently) cefdinir combined with a macrolide (azithromycin or clarithromycin) The brandname of cefdinir is Omnicef. As of 2007, data on penetration of cefdinir/Omnicef into the human cerebrospinal fluid, csf, are not available. (in cache: Clinical pharmacology, Omnicef drug info) Hunfeld KP, Rödel R, Wichelhaus TA, In vitro activity of eight oral cephalosporins against Borrelia burgdorferi, Int J Antimicrob Agents. 2003 Apr;21(4):313-8. R B Stricker, A Lautin, J J Burrascano, Lyme disease: point/counterpoint, Expert Rev Anti Infect Ther. 2005 Apr;3(2):155-65. (in Cache) Immune Electronmicroscopy: Hazelton PR and Gelderblom HR, Electron Microscopy for Rapid Diagnosis of Emerging Infectious Agents, Emerg Infect Dis [serial online] Volume 9, Number 3 (March 2003) Models of Immune Systems: The Use of Differential Equations, A Medline Literature Survey, (Date: 13. April 2000) Lyme and Immune Complexes - A Medline Literature Survey (Date: February 16, 2000) Mathematical Immune Response Models - A Medline Literature Survey (Date: March 29, 2000) Stricker RB and Phillips SE, Endorsement of Inadequate Treatment for Lyme Disease, Annals of Internal Medicine (submitted Marcj 2003) Demonstrating the Intracellularity of Borrelia burgdorferi, A compilation by Harold Smith (2000) Klempner MS, Huber BT, Is it thee or me? - autoimmunity in Lyme disease, Nature Medicine 5, 1346 - 1346-1347 (1999) Kuby J, Immunology, 3.ed, W.H. Freeman and Co,  New York (1997) Chapter 1 Excerpts from Chapters 1, 3 and 13 Cellular Interactions in Induction of Humoral and Cell-Mediated Immune Response Komplementsystem Leukozyten Lymphozyten Leukocyte migration and inflammation Leptospirose und Rattenurin Kuhn M, Informationen Medline Recherche "leptospirosis rat urine" biologische Leukozytenkurve: Leukozytenverteilung bei akutem bakteriellem Infekt [H. Begemann: Praktische Hämatologie, 8. Aufl.; Stuttgart 1982] Luger SW, Lyme-Borreliose übertragen von einer Stechfliege/Bremse, N. Engl.J.Med (NEJM). 1990 Jun 14;322(24):1752 Informationsveranstaltung des Borreliose Selbsthilfe e.V. Berlin-Brandenburg (2001) von Baehr R, Der Lymphozytentransformationstest für Borrelien: Neue diagnostische Möglichkeiten für Problemfälle Kursawe H, Klinik und Therapie der Neuroborreliose unter Einschluß der Pulstherapie" Luger SW, Lyme-Borreliose übertragen von einer Stechfliege/Bremse, N. Engl.J.Med (NEJM). 1990 Jun 14;322(24):1752 Christen HJ, Hanefeld F, Eiffert H, Thomssen R, Epidemiology and clinical manifestations of Lyme borreliosis in childhood. A prospective multicentre study with special regard to neuroborreliosis, Acta Paediatr Suppl 1993 Feb;386:1-75 Lyme Disease: Mechanisms, Resolution and Therapeutic Vaccination - A Medline-Literature Survey (19. February, 1999) Agarwal GS, (H. Bungay, III, Professor Emeritus, ed.), Microbial growth theory for biotreatment, Growth-limiting nutrient, TERM PROJECT: MICROBIOLOGY OF TREATMENT PROCESSES, Howard P. Isermann Department of Chemical & Biological Engineering, Department of Biomedical Engineering, Rensselaer Polytechnic Institute,  (Dec. 1994, Jan. 1995 and Feb. 1996) Fallon BA, Neilds JA, Microbiology of Borrelia burgdorferi, Special Article, The American Journal of Psychiatry 1994, 151:11, 1571-1583 Microbiology, Infections, and Antibiotic Therapy, Grand Rounds Presentation, UTMB, Dept. of Otolaryngology (22. March. 2000) Gruber J, The Inadequacy of the Minimum Inhibitory Concentration (MIC) concept - Illustrations. When a bacteria population can be exposed to an antibiotic in-vitro in the same way as it is in vivo, the in-vitro experiments quantify the efficacy of the antibiotic. When the antibiotic has strong side effects, one has to optimize between those effects and the risk of losing control over the bacteria population. In such critical cases an in-vitro model with only one parameter, the Minimum Inhibitory Concentration, may not be able to describe the development of an in-vitro bacteria population accurately enough. Stein Goldings A, Controversies in neuroborreliosis, Lyme Disease Conference (23 October, 1992) Niches Synonyms: immunologically priviledged or protected sites, protected states of existence (antigenic variation, cyst forms, slime layers) Goldhagen H, Rawlings J, Fighting Back: How B burgdorferi Persists, 14th International Scientific Conference on Lyme Disease & Other Tick-Borne Disorders, April 21-23, 2001; Hartford, Connecticut. There are at least 6 potential mechanisms (C. Pavia): antigenic variation (this is seen with the Borrelia species that cause tick-borne relapsing fever) or differential expression of antigens (especially the outer surface proteins; with B burgdorferi, only OspC is expressed during mammalian infection) production of an outer protective coat (eg, capsule, as seen with T pallidum) atypical forms (eg, cyst-like variants) incomplete immune response (eg, insufficient antibody , T-cell , or phagocytic response) deranged host immune response (eg, host-, tick-, or spirochete-derived immunosuppressive factors) other evasive factors (eg, motility) Pavia C, Mechanisms of persistency of the Lyme disease spirochete. Program and abstracts of the 14th International Scientific Conference on Lyme Disease and Other Tick-Borne Disorders; April 21-23, 2001; Hartford, Connecticut. An Appraisal of "Chronic Lyme Disease", Correspondence, N Engl J Med. 2008 Jan 24;358(4):428-431 (in Cache) Original article: Feder HM Jr, Johnson BJ, O'Connell S, Shapiro ED, Steere AC, Wormser GP; Ad Hoc International Lyme Disease Group, A critical appraisal of "chronic Lyme disease". N Engl J Med. 2007 Oct 4;357(14):1422-30 Relapse/Persistence of Lyme Disease Despite Antibiotic Therapy, LYME DISEASE MEDICAL LITERATURE SUMMARIES, Lyme Info, 16. September 2003 Analytic Perspective by Cameron DJ. Epidemiologic review of the generalizability of two clinical trials of Lyme disease conducted by Klempner et al., Epidemiologic Perspectives & Innovations, 2006 Pavlovic DM, Milovic AM, Dmitrovic R. Lyme Neuroborreliosis with Normal Cerebrospinal Fluid Findings, VIIth International Congress Lyme Borr, Abstract #D615 [Yugoslavian Study] Neuroborreliose: Einige Hintergründe für Krankheitsverlauf und lange Behandlungdauer, Literaturzusammenstellung, J. Gruber (2004) Niches: Long-Term Inflammation in Lyme Borreliosis, A Medline-Literature Survey (2001), augmented by J. Gruber Garth L. Nicolson, PhD (Department of Molecular Pathology, The Institute for Molecular Medicine, Huntington Beach, CA), Autoimmune Illnesses and Degenerative Diseases (in cache) Chronic Bacterial and Viral Infections in Neurodegenerative and Neurobehavioral Diseases, LABMEDICINE, Volume 39 Number 5, May 2008 (in cache) Garth L. Nicolson, J. Haier, Role of Chronic Bacterial and Viral Infections in Neurodegenerative, Neurobehavioral, Psychiatric, Autoimmune and Fatiguing Illnesses: Part 1, British Journal of Medical Practitioners 2009;2(4):20-28 (in cache, 12. August 2010), Part 2, British Journal of Medical Practitioners 2010;3(1):301-311 (in cache, 12. August 2010). Reactivation of Illnesses, JWissmille@aol.com, 25 Aug 2002 Prostate Cancer Diagnosis Prostate Cancer Diagnosis and Characterization: Literature overview by Claus FG, Hricak H and Hattery RR, enlarged by Gruber J Variation of the PSA Level: Influence of Frequency of Sexual Activity & Bicycling, Gruber J Lognormal distributions of PSA levels: evaluation of PSA relevant parameters, Gruber J Fritz Schardt (Betriebsärztliche Untersuchungsstelle, Bayerische Julius-Maximilians-Universitat, Würzburg, Germany) A New Approach to Chronic Lyme Disease (im Cache) ... Diflucan behindert ein Enzym mit Namen Cytochrom P450. Dies ist ein Enzym, das z.B. unsere Leber benutzt, um Chemikalien und Medikamente in ungiftige Formen zu überführen. Borrelia hat eine sehr primitive P450-Abwehr, sodaß -wenn man es behindert-, es leicht geschwächt wird. Daher glaube ich, daß Diflucan das Wachstum und die Vermehrung von Borrelien behindert. Es bringt sie nicht notwendigerweise um. Zusätzlich dringt es gut in Zellen ein und ins Nervensystem und das Gehirn, wo die Borrelien sich verstecken könnten... ... Diflucan war damals [als ich es zuerst benutzte] ein neues Medikament, das hauptsächlich gegen opportunistische Pilzinfektionen bei AIDS-Patienten eingesetzt wurde... Clinical effects of fluconazole in patients with neuroborreliosis, Eur J Med Res. 2004 Jul 30;9(7):334-6. Statine helfen gegen Multiple Sklerose - Deutschlandfunk, Forschung Aktuell, Newsletter, Kompaktinformationen aus Naturwissenschaft und Technik, 05.01.2005 Forscher fanden Substanz, die Entzündungen beim Nervensystem verlangsamen können. Wirt-Pathogen-Wechselwirkung Nature Insight: Host-microbe interactions, Nature Vol. 449, No. 7164:803-842. (Original) Interactions between symbiotic or pathogenic microbes and the hosts they colonize are central to both health and disease. This rapidly advancing field is now bearing the fruits of interdisciplinary efforts by microbiologists, immunologists, cell biologists, geneticists and ecologists. Artikel in Cache: Host-microbe interactions, Claudia Lupp, doi:10.1038/449803a (Original) The Human Microbiome Project, Peter J. Turnbaugh, Ruth E. Ley, Micah Hamady, Claire M. Fraser-Liggett, Rob Knight & Jeffrey I. Gordon, doi:10.1038/nature06244 (Original) An ecological and evolutionary perspective on human-microbe mutualism and disease, Les Dethlefsen, Margaret McFall-Ngai & David A. Relman, doi:10.1038/nature06245 (Original) Recognition of microorganisms and activation of the immune response, Ruslan Medzhitov, doi:10.1038/nature06246 (Original) Manipulation of host-cell pathways by bacterial pathogens, Amit P. Bhavsar, Julian A. Guttman & B. Brett Finlay, doi:10.1038/nature06247 (Original) Bacterial pathogenomics, Mark J. Pallen & Brendan W. Wren, doi:10.1038/nature06248 (Original)